A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy

| April 23, 2009 | 0 Comments

by Robert A. Lasser, MD, MBA; Nina R. Schooler, PhD; Mary Kujawa, MD, PhD;
Kathleen Jarboe, PHMCNS-BC; John Docherty, MD; and Peter Weiden, MD

Dr. Lasser is with Shire Pharmaceuticals (Dr. Lasser was with Johnson & Johnson at the time of the development of this manuscript); Dr. Schooler is with SUNY Downstate Medical Center, Brooklyn, New York; Dr. Kujawa is with Hoffman-La Roche, Nutley, New Jersey (Dr. Kujawa was with Ortho-McNeil Janssen Pharmaceutical Affairs, LLC, at the time of the development of this manuscript); K. Jarboe is with Quintiles, Inc., Atlanta, Georgia; Dr. Docherty is with Joan and Sanford I. Weill Medical College of Cornell University, New York, New York; and Dr. Weiden is with the University of Illinois, Chicago, Illinois.

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , , , ,

Category: Brief Report, Psychiatry, Psychology, Report, Schizophrenia

Leave a Reply